| Revenue growth | 4.8% YoY for FY26; 9.4% YoY for Q4 FY26. |
|---|---|
| Margins | Consolidated EBITDA margin steady at 14.5% for FY26. |
| Demand visibility | Strong surgery counts in Oncology and Nephro-Urology segments. |
| Management confidence | High in 'Zero Technique' and multi-specialty diversification. |
Growth
FY26 Consolidated Revenue reached ₹11,682 mn (up 4.8% YoY); PAT surged 1706% YoY to ₹347 mn due to tax regime adoption.
Outlook
Targeting 2200+ beds across 10 cities; focusing on doubling ROCE through operational leverage and asset-light O&M models.
Risks
International business (Delhi-NCR) reported EBITDA losses; hospital occupancy remains relatively low at 48%.
Earnings Call filed with BSE, NSE: SHALBY. Summary written with AI assistance from the document.
Shalby Ltd: key numbers
- Share price
- ₹135.00
- Market cap
- ₹1,458 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 37.1×Sector 53.1×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Management Change
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
Shalby Annual General Meeting
Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.
Shalby Other Announcement
Shalby Limited has issued a letter to shareholders providing the web-link for the Annual Report for FY 2025-26. The 22nd Annual General Meeting is scheduled for September 10, 2026.
Shalby Business Update
Shalby Limited filed its Business Responsibility & Sustainability Report (BRSR) for FY 2025-26 as mandated by SEBI LODR regulations.
Shalby Annual General Meeting
Shalby Ltd announced its 22nd Annual General Meeting scheduled for September 10, 2026, and filed its Annual Report for FY 2025-26.
Shalby Earnings Call Transcript: Key Takeaways
Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.
- Call
- Guides 20% growth